Gefapixant - Merck & Co
Alternative Names: AF-219; Gefapixant citrate - Merck & Co; Gefzuris; LYFNUA; MK-7264; R 1646; RG-1646; RO-4926219Latest Information Update: 06 Sep 2024
At a glance
- Originator Roche
- Developer Merck & Co; Roche
- Class Amines; Analgesics; Antiasthmatics; Antitussives; Benzene derivatives; Ethers; Pyrimidines; Sleep disorder therapies; Small molecules; Sulfonamides
- Mechanism of Action Purinergic P2X3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Cough
- Discontinued Asthma; Interstitial cystitis; Musculoskeletal pain; Overactive bladder; Pain; Pelvic pain; Sleep apnoea syndrome
Most Recent Events
- 20 Dec 2023 Merck & Co receives complete response letter from the US FDA for gefapixant in Cough
- 31 Jul 2023 US FDA accepts Merck’s resubmission of the NDA for gefapixant in Cough in USA, following the company’s response to the complete response letter (Merck & Co pipeline, August 2023).
- 21 Jul 2023 Merck expects the EC decision on approval of gefapixant for Cough in late 2023